Table 2.
Baseline echocardiographic and cardiopulmonary exercise test data, according to treatment.
| Variables | Sacubitril/Valsartan (n = 12) | Control Group (n = 13) | p Value |
|---|---|---|---|
| Echocardiographic parameters | |||
| LVEF (%) | 30.7 ± 4.0 | 32.3 ± 5.1 | 0.4 |
| LVEDVi (mL/m2) | 116.0 ± 36.9 | 129.6 ± 32.4 | 0.4 |
| LVESVi (mL/m2) | 80.6 ± 27.9 | 86.0 ± 33.7 | 0.7 |
| TAPSE (mm) | 17.5 (16.2–21.2) | 18 (16–21.5) | 0.8 |
| sPAP (mmHg) | 32.1 ± 8.7 | 39.2 ± 9.6 | 0.1 |
| LAVi (mL/m2) | 44.2 ± 15.4 | 46.8 ± 15.6 | 0.7 |
| E/e’ ratio | 16.0 ± 7.5 | 15.2 ± 9.5 | 0.9 |
| Cardiopulmonary exercise test data | |||
| PeakVO2 (mL/kg/min) | 12.2 ± 4.6 | 13.1 ± 4.2 | 0.6 |
| VE/VCO2 slope | 35.4 ± 7.4 | 34.6 ± 9.1 | 0.8 |
| Predicted peak VO2, % | 61.5 ± 25.7 | 59.2 ± 20.7 | 0.8 |
LVEF: left ventricular ejection fraction; LVEDVi: left ventricular end-diastolic volume index; LVESVi: left ventricular end-systolic volume index; E: early-wave transmitral diastolic velocity; e’: early-diastolic velocity at tissue Doppler imaging; TAPSE: tricuspid annular plane systolic excursion; sPAP: pulmonary artery systolic pressure; LAVi: left atrial volume index; VO2: oxygen consumption; VE/VCO2: minute ventilation to carbon dioxide production.